These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 900875)

  • 1. [Plasma growth hormone in obese patients. Comparison of response to arginine and L-dopa (author's transl)].
    Wolf LM; Ericher S; Houdent C
    Ann Endocrinol (Paris); 1977; 38(2):173-4. PubMed ID: 900875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related decrease in plasma growth hormone: response to growth hormone-releasing hormone, arginine, and L-dopa in obesity.
    Tanaka K; Inoue S; Shiraki J; Shishido T; Saito M; Numata K; Takamura Y
    Metabolism; 1991 Dec; 40(12):1257-62. PubMed ID: 1961117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients.
    Hansen AP; Christensen SE; Lundbaek K
    Scand J Clin Lab Invest; 1975 May; 35(3):205-10. PubMed ID: 1153917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone response to L-dopa in the thinned obese.
    Laurian L; Oberman Z; Hoerer E; Wiznitzer T; Harell A
    Isr J Med Sci; 1982 May; 18(5):625-9. PubMed ID: 7096047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of l-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects.
    Vizner B; Reiner Z; Sekso M
    Exp Clin Endocrinol; 1983 Jan; 81(1):41-8. PubMed ID: 6343098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blindness impairs plasma growth hormone response to L-dopa but not to arginine.
    Bellastella A; Parlato F; Sinisi AA
    J Clin Endocrinol Metab; 1990 Apr; 70(4):856-8. PubMed ID: 2318945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone response to propranolol and L--dopa in obese subjects.
    Barbarine A; De Marinis L; Troncone L
    Metabolism; 1978 Mar; 27(3):275-8. PubMed ID: 628352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
    Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D
    Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].
    Carmina E; Lanzara P; Lo Coco R; Longo RA; Jannì A
    Arch Sci Med (Torino); 1979; 136(3):421-5. PubMed ID: 549547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of biological and hormonal diagnostic criteria in acromegaly (author's transl)].
    Bodson A; Crabbé J
    Ann Endocrinol (Paris); 1980; 41(3):225-6. PubMed ID: 6774658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa, growth hormone and adipokinesis in the lean and the obese.
    Pinter EJ; Tolis G; Friesen HG
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):277-80. PubMed ID: 1165135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circadian variations in the plasma GH response to L-dopa stimulation in female obesity].
    D'Alessandro B; Bellastella A; Cafaro MR; De Luca R; Esposito V
    Boll Soc Ital Biol Sper; 1977 Dec; 53(23):2333-6. PubMed ID: 610754
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced growth hormone response to L-dopa and pyridostigmine in obesity.
    Lee EJ; Kim KR; Lee KM; Lim SK; Lee HC; Lee JH; Lee DJ; Huh KB
    Int J Obes Relat Metab Disord; 1994 Jul; 18(7):465-8. PubMed ID: 7920871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behavior of HGH after oral administration of L-dopa in normal and obese subjects].
    Carducci Artenisio A; Ragonese F; Albanese MC; Alibrando S; Allegra V
    Boll Soc Ital Biol Sper; 1974 Aug; 50(13):946-52. PubMed ID: 4463984
    [No Abstract]   [Full Text] [Related]  

  • 15. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency.
    Biller BM; Samuels MH; Zagar A; Cook DM; Arafah BM; Bonert V; Stavrou S; Kleinberg DL; Chipman JJ; Hartman ML
    J Clin Endocrinol Metab; 2002 May; 87(5):2067-79. PubMed ID: 11994342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone response in very short children.
    Palayew K; Crock P; Pianosi P; Coates A; Weitzner G; Schiffrin A
    Clin Invest Med; 1991 Aug; 14(4):331-7. PubMed ID: 1782731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of dopaminergic and alpha-adrenergic function in children with growth hormone neurosecretory dysfunction.
    Bercu BB; Root AW; Shulman DI
    J Clin Endocrinol Metab; 1986 Oct; 63(4):968-73. PubMed ID: 3018032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 19. [Tests of somatotropin reserve in obesity: response of GH to stimulation with L-DOPA and L-arginine].
    D'Alessandro B; Bellastella A; Esposito V; Gasbarro R
    Folia Endocrinol; 1974 Aug; 27(4):381-9. PubMed ID: 4408121
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.